Arsenault, Daniel <br/><br/>
Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.  [electronic resource] 

 -  American journal of clinical oncology  Aug 2015 
 - 348-52 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1537-453X 
<br/><br/><label>Standard No.: </label>10.1097/COC.0b013e31829d1eb8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Carcinoma, Ductal, Breast--drug therapy<br/>Chemotherapy, Adjuvant<br/>Cohort Studies<br/>Female<br/>Humans<br/>Lymph Nodes--pathology<br/>Mastectomy<br/>Mastectomy, Segmental<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Neoplasm Recurrence, Local<br/>Neoplasm Staging<br/>Neoplasm, Residual<br/>Radiotherapy, Adjuvant<br/>Receptor, ErbB-2--metabolism<br/>Receptors, Estrogen--metabolism<br/>Retrospective Studies<br/>Risk Factors<br/>Trastuzumab